Fidelity Biosciences News - Fidelity Biosciences invests venture capital in private biopharmaceutical and medical technology companies.

WuXi PharmaTech Announces First-Quarter 2010 Results

	Printable Version
	Send to a Colleague

Shanghai, China, May 12, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for first-quarter 2010.

Highlights

First-Quarter 2010 Net Revenues Increased 36% Year Over Year to $80.6 Million
Laboratory Services Net Revenues Grew 18% Year Over Year to $67.0 Million, Driven by Strong Organic Growth
China-Based Laboratory Services Net Revenues Increased 20% Year Over Year to $50.0 Million
Manufacturing Services Net Revenues Grew 433% Year Over Year to $13.6 Million
GAAP Diluted Earnings Per ADS Grew 30% Year Over Year to 21 Cents
Non-GAAP Diluted Earnings Per ADS Increased 26% Year Over Year to 25 Cents
Company Believes It Will Achieve Upper End of Previous Guidance Ranges for 2010 Net Revenues and Operating Income

Management Comment

"We were pleased with our performance in the first quarter,” said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. “The quarter was characterized by strong year-over-year revenue growth in both our Laboratory Services and Manufacturing Services businesses and continued investment in new opportunities to propel future revenue growth.”

“WuXi achieved a strong performance in revenues, gross profit, operating income and net income in the first quarter,” said Edward Hu, Chief Operating Officer. “Revenues in our Laboratory Services business grew 18% year over year in the quarter, driven by growing demand. This performance in Laboratory Services was broad-based, with 20% year-over-year growth in China-based operations and 14% yearover- year revenue growth in U.S.-based operations. Revenues in Manufacturing Services grew 433% year over year from improving demand and delivery of a large order, which we spoke about in our fourth-quarter 2009 earnings release. The company’s margin performance was consistent with our expectations. We continue to expect strong financial performance throughout 2010 and beyond.”

For the full press release, Click Here.